Our mission is to expedite discoveries and innovations across Texas to reduce the burden of cancer.
The University of Texas at Austin could be the epicenter for a game-changing cancer-detection technology—the MasSpec Pen—a device that can rapidly identify breast, thyroid, lung, ovarian and brain cancers with more than 96 percent accuracy.

A team of scientists led by Dr. Livia Schiavinato Eberlin is using CPRIT grants totaling $2.2 million to date to push the development of the MasSpec pen forward. The pen enables a controlled and automated delivery of a discrete water droplet to a tissue surface for efficient extraction of biomolecules, which are then delivered to a mass spectrometer for molecular analysis.

In 2016, Dr. Eberlin came to Austin to be an assistant professor in the chemistry department at the University of Texas and is a 2018 MacArthur Foundation “Genius” Awardee.

---

**THE IMMUNOTHERAPY FRONTIER**

Between 1982 and 1996, Dr. Jim Allison and his colleagues hunted for, and succeeded in discovering, a protein in the human body, CTLA-4. They proved it behaves like a brake on the immune system, contrary to the view most researchers held at the time. The discovery led to the development of the drug Yervoy.

In 2011, Dr. Allison was recruited from Memorial Sloan-Kettering to MD Anderson with the help of a $10M CPRIT grant to advance his groundbreaking checkpoint inhibitor research and translate the discovery into drugs capable of unleashing the body’s immune system to attack cancer cells.

Today, Dr. Allison leads the Immunology Department at MD Anderson Cancer Center and has a combination of talented research associates and laboratory infrastructure working together to translate cancer immunotherapies to the bedside. Dr. Allison is the recipient of the 2018 Nobel Prize in Physiology or Medicine along with Tasuku Honjo.

---

**INNOVATION IN THE STATE’S CAPITAL**

The University of Texas at Austin could be the epicenter for a game-changing cancer-detection technology—the MasSpec Pen—a device that can rapidly identify breast, thyroid, lung, ovarian and brain cancers with more than 96 percent accuracy.

A team of scientists led by Dr. Livia Schiavinato Eberlin is using CPRIT grants totaling $2.2 million to date to push the development of the MasSpec pen forward. The pen enables a controlled and automated delivery of a discrete water droplet to a tissue surface for efficient extraction of biomolecules, which are then delivered to a mass spectrometer for molecular analysis.

In 2016, Dr. Eberlin came to Austin to be an assistant professor in the chemistry department at the University of Texas and is a 2018 MacArthur Foundation “Genius” Awardee.

---

**PRODUCT DEVELOPMENT RESEARCH PROGRAM**

- **40** Product Development Research Grants
- **22** Companies Conducting Clinical Trials
- **$411,198,243** Amount of Product Development Research Grants
- **17** Follow-On Funding

---

“As I learned more about immunotherapy and the advancements of Dr. Allison and what he has done, I was blessed to hear that he was obviously back in Texas doing the work that all cancer patients need”

— Karlee Steele, Cancer Survivor

---

In 2011, Dr. Allison was recruited from Memorial Sloan-Kettering to MD Anderson with the help of a $10M CPRIT grant to advance his groundbreaking checkpoint inhibitor research and translate the discovery into drugs capable of unleashing the body’s immune system to attack cancer cells.

Today, Dr. Allison leads the Immunology Department at MD Anderson Cancer Center and has a combination of talented research associates and laboratory infrastructure working together to translate cancer immunotherapies to the bedside. Dr. Allison is the recipient of the 2018 Nobel Prize in Physiology or Medicine along with Tasuku Honjo.

---

In 2011 Karlee Steele was diagnosed with stage 1 melanoma on her skin. It was treated through a simple procedure.

In 2015, Karlee faced a second melanoma diagnosis that had spread to the lymph node under her right arm. At MD Anderson, Karlee learned the cancer had developed into a stage 3B melanoma tumor.

Karlee was treated by the immunotherapy pioneered by Dr. Allison and today, is cancer free.

— Karlee Steele, Cancer Survivor

---

In 2011 Karlee Steele was diagnosed with stage 1 melanoma on her skin. It was treated through a simple procedure.

In 2015, Karlee faced a second melanoma diagnosis that had spread to the lymph node under her right arm. At MD Anderson, Karlee learned the cancer had developed into a stage 3B melanoma tumor.

Karlee was treated by the immunotherapy pioneered by Dr. Allison and today, is cancer free.

— Karlee Steele, Cancer Survivor

---

The Immunotherapy Frontier

Between 1982 and 1996, Dr. Jim Allison and his colleagues hunted for, and succeeded in discovering, a protein in the human body, CTLA-4. They proved it behaves like a brake on the immune system, contrary to the view most researchers held at the time. The discovery led to the development of the drug Yervoy.

In 2011, Dr. Allison was recruited from Memorial Sloan-Kettering to MD Anderson with the help of a $10M CPRIT grant to advance his groundbreaking checkpoint inhibitor research and translate the discovery into drugs capable of unleashing the body’s immune system to attack cancer cells.

Today, Dr. Allison leads the Immunology Department at MD Anderson Cancer Center and has a combination of talented research associates and laboratory infrastructure working together to translate cancer immunotherapies to the bedside. Dr. Allison is the recipient of the 2018 Nobel Prize in Physiology or Medicine along with Tasuku Honjo.

---

In 2011 Karlee Steele was diagnosed with stage 1 melanoma on her skin. It was treated through a simple procedure.

In 2015, Karlee faced a second melanoma diagnosis that had spread to the lymph node under her right arm. At MD Anderson, Karlee learned the cancer had developed into a stage 3B melanoma tumor.

Karlee was treated by the immunotherapy pioneered by Dr. Allison and today, is cancer free.

— Karlee Steele, Cancer Survivor

---

The University of Texas at Austin
1,116 Academic Research Grants
$1,613,732,784 Amount of Academic Research Grants
170 CPRIT Scholars Recruited to Texas
$504,073,604 Amount of Recruitment Grants

Building Bridges Between the Private Sector & Academic Institutions

2015
German immunotherapy company Immatics Biotechnologies, one of 32 CPRIT grant recipients, opened a US office in Houston after receiving a grant from CPRIT for $19.7 million. Immatics has matched the award with $40 million in private equity follow-on funding.

2017
Immatics US Inc. President and CEO Harpreet Singh struck up a strategic partnership with MD Anderson Cancer Center’s Division Head of Cancer Medicine Patrick Hwu, who is a recipient of over $4 million in CPRIT Academic Research grants, and CPRIT Scholar Cassian Yee, Director of Solid Tumor Cell Therapy, who was recruited to Texas from the Fred Hutchinson Cancer Research Center in Seattle, Washington. Through this collaboration, Immatics US initiated cutting-edge immunotherapy clinical trials in 2017, working to further develop and potentially commercialize immunotherapy research at MD Anderson.

TODAY
The company has established a state-of-the-art research and development and GMP manufacturing facility at the Life Science Plaza in Houston that currently employs 50 full-time staff. This collaboration contributed to a new partnership with biopharmaceutical giant Amgen, yielding $30 million in additional funding.

109 clinical studies in Texas
13,418 patients enrolled through CPRIT programs
CREATING ACCESS TO BREAST AND CERVICAL CANCER SCREENINGS IN WEST TEXAS

The Texas Panhandle is largely comprised of rural, medically underserved communities facing socio-economic and geographical barriers that limit access to health care. In 2010, more women on a percentile basis died from breast cancer in the Texas Panhandle than the rest of the state. The 26-county region also has the highest cervical cancer mortality rate in the state.

CPRIT awarded a prevention grant to Dr. Rakhshanda Rahman of the Amarillo Breast Center of Excellence at Texas Tech University Health Sciences Center to deliver breast and cervical cancer services in the Texas Panhandle.

The program—Access to Breast and Cervical Care for West Texas—has increased the number of screening mammograms year-over-year by 26 percent since 2009, reducing the percentage of late stage breast cancers from 21.2% to 4.5% in the 26-county region. The annual number of Pap tests increased by 21% since 2013, with the number of HPV vaccinations increasing by an incredible 94%. These efforts are significantly reducing the emotional and economic burden of cancer in the Texas Panhandle.

“I was told about the breast cancer screening funded by the CPRIT project, available for women just like me with no job and no insurance. I was so thankful my cancer was spotted early. Thank you for allowing this true blessing to be available to the patients of the Texas Panhandle and surrounding areas.”

— Martha, patient of Dr. Rahman

Delivered 5.2 million prevention services to Texans from all 254 counties

<table>
<thead>
<tr>
<th>PREVENTION PROGRAM</th>
</tr>
</thead>
<tbody>
<tr>
<td>▼ 216 Prevention Grants</td>
</tr>
<tr>
<td>▼ $235,469,167 Amount of Prevention Grants</td>
</tr>
<tr>
<td>▼ 2,608,754 Education and Training Services Provided</td>
</tr>
<tr>
<td>▼ 2,630,217 Clinical Services Provided. Includes 1,256,971 screening and diagnostics, with 15,292 cancer precursors and 3,584 cancers detected</td>
</tr>
</tbody>
</table>

- 2-6 Projects
- 7-11 Projects
- 12-16 Projects
- 17-23 Projects
- 24-34 Projects
- 35-53 Projects
- Statewide/Dissemination Projects: 40